<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347318</url>
  </required_header>
  <id_info>
    <org_study_id>001-IRCC-00IIS-10</org_study_id>
    <nct_id>NCT03347318</nct_id>
  </id_info>
  <brief_title>Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease</brief_title>
  <acronym>PROFILING</acronym>
  <official_title>Non-interventional Study for the Determination of Molecular Resistance Profiling to Targeted Therapies in Patients With Neoplastic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione del Piemonte per l'Oncologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione del Piemonte per l'Oncologia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to define the molecular profile of selected solid tumors.
      From each participants will be collected biological materials for molecular analysis,
      including saliva, blood and vital tumor tissue derived form surgical or biopsy procedures.
      Whereas possible, vital tumor specimens will be inoculated and propagated in
      immunocompromised NOD/SCID mice to study the genetic correlations between genetic status and
      response to target drugs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of patient correctly sampled</measure>
    <time_frame>through study completion, an average of five years</time_frame>
    <description>number of patients with biological samples idoneous for molecular profiling testing (nucleic acid extraction, protein) over all recruited patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients with detected genetic alterations that respond to treatments assigned by physician.</measure>
    <time_frame>through study completion, an average of five years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Solid Tumors</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, saliva, feces, urine and tumor specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with selected solid tumors (CRC, Prostate Cancer, Head &amp; Neck Cancer, Gastric
        Cancer, Glioblastoma, Breast Cancer, Hepatocarcinoma, Biliary Tract Carcinoma, Lung Cancer,
        Rare Tumors, Metastatic Sarcoma and Metastatic Melanoma).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with at least one of the following selected solid tumors:

          -  Colorectal Cancer (primary or with synchronous/metachronous liver metastases)

          -  Prostate Cancer

          -  Head &amp; Neck Tumors

          -  Gastric Cancer

          -  Glioblastoma

          -  Breast Cancer

          -  Hepatocarcinoma

          -  Biliary Tract Carcinoma

          -  Lung Cancer (primary)

          -  Rare Tumors (incidence ≤ 5x10-6)

          -  Metastatic Sarcoma

          -  Metastatic Melanoma

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silvia Marsoni, MD</last_name>
    <email>silvia.marsoni@ircc.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale Regionale Umberto Parini</name>
      <address>
        <city>Aosta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Trogu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Ardizzoni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Di Candiolo - Fondazione Del Piemonte Per L'Oncologia (FPO-Irccs)</name>
      <address>
        <city>Candiolo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Marsoni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Mini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS - Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo De Braud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Niguarda Ca'Granda</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Siena, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IEO - Istiuto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Curigliano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU S. Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Novello, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IOV - Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorina Zagonel, MD</last_name>
      <email>vittorina.zagonel@iov.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Falcone, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Tonini, MD</last_name>
      <email>g.tonini@unicampus.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Città della Salute e della Scienza di Torino - Presidio ospedaliero Ostetrico Ginecologico Sant'Anna</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Gregori, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino - Presidio Molinette</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Cassoni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano Umberto I</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Ferrero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Martini</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Crosetti, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

